A study for a 40 year old man who takes Rosuvastatin Zinc - from FDA reports


81 males aged 40 (±5) who take the same drug are studied. This is a personalized study for a 40 year old male patient who has High Cholesterol. The study is created by eHealthMe based on reports from FDA.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our independent and original studies have been referenced on 400+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO.



On Jun, 13, 2018

81 males aged 40 (±5) who take Rosuvastatin Zinc are studied.


Number of reports submitted per year:

Rosuvastatin Zinc for a 40-year old man.

Information of the patient in this study:

  • Age: 40
  • Gender: male
  • Conditions: High Cholesterol
  • Drugs taken:
    • Rosuvastatin Zinc (rosuvastatin zinc)

eHealthMe real world results:

Comparison with this patient's adverse outcomes:

  • Muscular Weakness(muscle weakness): 0 (0% of males aged 40 (±5) who take the drug)

As an adverse outcome could be a symptom of a condition, additional studies are listed to help identify the cause: for example, regardless of which drug is taken, how many female HBP patients aged 50 (±5) have nausea

As an adverse outcome could be a side effect of a drug, additional studies are listed to help identify the cause: for example, how many female Aspirin users aged 50 (±5) have nausea

Most common side effects over time

< 1 month:
n/a
1 - 6 months:
n/a
6 - 12 months:
n/a
1 - 2 years:
n/a
2 - 5 years:
n/a
5 - 10 years:
n/a
10+ years:
n/a
not specified:
  1. Hypoglycemia (low blood sugar)
  2. Intentional overdose
  3. Arrhythmias (irregular heartbeat)
  4. Thrombocytopenia (decrease of platelets in blood)
  5. Fever

Top conditions involved for these people *:

  1. High Blood Pressure : 16 people, 19.75%
  2. Pain : 10 people, 12.35%
  3. Type Iia Hyperlipidaemia (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood- type iia): 10 people, 12.35%
  4. Type 2 Diabetes : 10 people, 12.35%
  5. Diabetes : 10 people, 12.35%

Top co-used drugs for these people *:

  1. Metformin (23 people, 28.40%)
  2. Zolpidem (10 people, 12.35%)
  3. Juxtapid (8 people, 9.88%)
  4. Lantus (7 people, 8.64%)
  5. Zetia (6 people, 7.41%)

* Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Want to find out more about the FDA reports used in the study? You can request them from FDA.

You are not alone: Connect with people like you, or share your experience to help people like you.

What are the drugs?

What are the conditions?

What are the symtoms?

Could your drugs cause:

Could your conditions cause:



Related studies:

Related publications that referenced our studies

You may be interested in these posts

More posts for: Rosuvastatin zinc, High cholesterol, Muscular weakness

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.